Systemic lupus erythematosus (SLE) can be a severe and potentially life-threatening disease that often represents a therapeutic challenge because of its heterogeneous organ manifestations. Only glucocorticoids, hydroxychloroquine, mycophenolate mofetil, azathioprine, cyclophosphamide, and very recently belimumab have been approved for SLE therapy. Dependence on glucocorticoids and resistance to...

The parotid gland may enlarge during the course of systemic lupus erythematosus (SLE). Shearn and Pirofsky (1952) were the first to draw attention to this association while studying a group of 34 patients who had systemic lupus erythematosus. They discovered sialoadenitis characterized by chronic, nonsuppurative inflammation unilaterally in one and bilaterally in two patients. Morgan (1954) rep...

Thrombosis is a well-known clinical entity in systemic lupus erythematosus (SLE), and it is multifactorial. The most important risk factor is the presence of antiphospholipid antibodies (APLAs). However, approximately 40% of adults with SLE who are negative for APL A are diagnosed with thrombosis, indicating the importance of other risk factors. Thus, the thrombosis risk factors should be evalu...

The association of porphyria cutanea tarda (PCT) and systemic lupus erythematosus (SLE) is rare. Systemic lupus erythematosus, of complex pathophysiology and pleomorphic clinical manifestations, is similar to PCT regarding photosensitivity. One finding that can differentiate both diseases is the presence of cutaneous blisters, which are rare in SLE, but characteristic of PCT. We report one case...

Background: Antiphospholipid antibody syndrome (APS) can either occur as a primary syndrome or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in blood, measured by a standardized ELISA is the most acceptable laboratory criteria. APS IgG isotype, particularly IgG2 subclass is more strongly associated ...

manifestation of chorea in patients with systemic lupus erythematosus (sle) and antiphospholipid antibody syndrome (apa synd.) is not common. moreover, primary presentation of the disease with chorea is rare and only few such cases are reported in literature in recent years. we report here the case of a 28 year old woman who was first seen at the age of 10 with clinical manifestations of chorea...

Background: Systemic lupus erythematosus is a systemic autoimmune disorder with unclear etiology. The importance of some genes in the development of systemic lupus erythematosus has been implicated. The gene polymorphism in codon 72 has attracted a lot of attention and its role in the occurrence or progression of many cancers and autoimmune diseases especially systemic lupus erythematosus has ...

Drug development for the treatment of systemic lupus erythematosus (SLE) has largely focused on B-cell therapies. A greater understanding of the immunopathogenesis of SLE coupled with advanced bioengineering has allowed for clinical trials centered on other targets for SLE therapy. The authors discuss the benefits and shortcomings of focusing on T-cell-directed therapies in SLE and lupus nephri...

817 Rev Bras Reumatol 2012;52(6):817-818 In adults with systemic lupus erythematosus (SLE), antinucleosome antibodies have already been described as markers of disease activity and lupus nephritis.1–4 In addition, anti-C1q and antinucleosome antibodies have an amplifying effect on the etiopathogenesis of lupus nephritis in adults.5 In this issue of the Brazilian Journal of Rheumaotlogy, Jesus e...